Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

NCT03753243 is registered in ClinicalTrials.gov with Mark Garzotto, MD as lead sponsor.

NCT NCT03753243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03753243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Lead sponsor
Mark Garzotto, MD
Phase
Phase 2
Overall status
Recruiting
Start date
December 3, 2018
Completion date
April 30, 2023
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer